Netherlands

Byondis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Byondis Initiates Phase II Study of Antibody-Drug Conjugate [Vic-]Trastuzumab Duocarmazine in Advanced Endometrial Cancer

Lead Product(s): (vic-) trastuzumab duocarmazine

Therapeutic Area: Oncology Product Name: SYD985

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 15, 2020

Details:

A single-arm Phase II trial to evaluate the safety and efficacy of the antibody-drug conjugate in patients with HER2-expressing endometrial carcinoma who previously progressed on or after first-line platinum-based chemotherapy.

ISA Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

ISA Pharmaceuticals Receives US Orphan-Drug Designation for ISA101b in HPV16-Positive Cervical Cancer

Lead Product(s): ISA101b,Cemiplimab

Therapeutic Area: Oncology Product Name: ISA101b

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2020

Details:

ISA101b is a clinical-stage immunotherapy targeting HPV16-induced diseases such as cervical and oropharyngeal cancer. It induces specific immune responses to the oncogenic E6 and E7 proteins of HPV16 and is based on ISA's proprietary Synthetic Long Peptide (SLP®) technology.

DCprime

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Netherlands

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

DCprime Extends International Roll-out of DCP-001 Into the United States

Lead Product(s): DCP-001

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

The IND provides the possibility for DCprime to expand the ongoing ADVANCE-II trial into the Unites States, where DCP-001 had received orphan drug status.